{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:38:55Z","timestamp":1787582335580,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004569","name":"Ministerstwo Nauki i Szkolnictwa Wy\u017cszego","doi-asserted-by":"publisher","award":["641\/N-TREAT\/09\/2010\/0"],"award-info":[{"award-number":["641\/N-TREAT\/09\/2010\/0"]}],"id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","award":["1WC\/5BIOGEN\/17"],"award-info":[{"award-number":["1WC\/5BIOGEN\/17"]}],"id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Spinal muscular atrophy (SMA) is one of the most frequent and severe genetic diseases leading to premature death or severe motor disability. New therapies have been developed in recent years that change the natural history of the disease. The aim of this study is to describe patients included in the Polish Registry of SMA, with a focus on the course of type 3 SMA (SMA3) before the availability of disease-modifying treatments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>790 patients with SMA were included in the registry (173 with type 1 [SMA1], 218 with type 2 [SMA2], 393 with SMA3, and six with type 4 SMA [SMA4]), most (52%) of whom were adults. Data on <jats:italic>SMN2<\/jats:italic> gene copy number were available for 672 (85%) patients. The mean age of onset was 5\u00a0months for SMA1, 11.5\u00a0months for SMA2, and 4.5\u00a0years for SMA3. In patients with SMA3, the first symptoms occurred earlier in those with three copies of <jats:italic>SMN2<\/jats:italic> than in those with four copies of <jats:italic>SMN2<\/jats:italic> (3.2\u00a0years vs. 6.7\u00a0years). The age of onset of SMA3 was younger in girls than in boys (3.1\u00a0years vs. 5.7\u00a0years), with no new cases observed in women older than 16\u00a0years. Male patients outnumbered female patients, especially among patients with SMA3b (49 female vs. 85 male patients) and among patients with SMA3 with four copies of <jats:italic>SMN2<\/jats:italic> (30 female vs. 69 male patients). 44% of patients with SMA3 were still able to walk; in those who were not still able to walk, the mean age of immobilization was 14.0\u00a0years. Patients with SMA3a (age of onset\u2009&lt;\u20093\u00a0years) and three copies of <jats:italic>SMN2<\/jats:italic> had significantly worse prognosis for remaining ambulant than patients with SMA3b (age of onset\u2009\u2265\u20093\u00a0years) and four copies of <jats:italic>SMN2<\/jats:italic>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The Registry of SMA is an effective tool for assessing the disease course in the real world setting. <jats:italic>SMN2<\/jats:italic> copy number is an important prognostic factor for the age of onset and ambulation in SMA3. Sex and age of disease onset also strongly affect the course of SMA. Data supplied by this study can aid treatment decisions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-01771-y","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T20:07:57Z","timestamp":1616616477000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy"],"prefix":"10.1186","volume":"16","author":[{"given":"Anna","family":"Lusakowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jedrzejowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kaminska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Janiszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Grochowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Zimowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Sierdzinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kostera-Pruszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"issue":"4","key":"1771_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3233\/JND-190428","volume":"6","author":"K Vill","year":"2019","unstructured":"Vill K, K\u00f6lbel H, Schwartz O, Blaschek A, Olgem\u00f6ller B, Harms E, et al. One year of newborn screening for SMA\u2014results of a German pilot project. J Neuromuscul Dis. 2019;6(4):503\u201315.","journal-title":"J Neuromuscul Dis"},{"issue":"7","key":"1771_CR2","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00415-017-8549-1","volume":"264","author":"IE Verhaart","year":"2017","unstructured":"Verhaart IE, Robertson A, Leary R, McMacken G, K\u00f6nig K, Kirschner J, et al. A multi-source approach to determine SMA incidence and research ready population. J Neurol. 2017;264(7):1465\u201373.","journal-title":"J Neurol"},{"issue":"3","key":"1771_CR3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000275492","volume":"34","author":"M J\u0119drzejowska","year":"2010","unstructured":"J\u0119drzejowska M, Milewski M, Zimowski J, Zago\u017cd\u017con P, Kostera-Pruszczyk A, Borkowska J, et al. Incidence of spinal muscular atrophy in Poland - more frequent than predicted? Neuroepidemiology. 2010;34(3):152\u20137.","journal-title":"Neuroepidemiology"},{"key":"1771_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ana.24864","volume":"81","author":"MA Farrar","year":"2017","unstructured":"Farrar MA, Park SB, Vucic S, Carey KA, Turner BJ, Gillingwater TH, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017;81:355\u201368.","journal-title":"Ann Neurol"},{"issue":"1","key":"1771_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","volume":"146","author":"K Zerres","year":"1997","unstructured":"Zerres K, Rudnik-Sch\u00f6neborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III): 569 patients. J Neurol Sci. 1997;146(1):67\u201372.","journal-title":"J Neurol Sci"},{"key":"1771_CR6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","volume":"52","author":"K Zerres","year":"1995","unstructured":"Zerres K, Rudnik-Sch\u00f6neborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52:518\u201323.","journal-title":"Arch Neurol"},{"key":"1771_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155.","journal-title":"Cell"},{"issue":"3","key":"1771_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9","volume":"15","author":"B Wirth","year":"2000","unstructured":"Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat. 2000;15(3):228\u201337.","journal-title":"Hum Mutat"},{"issue":"7","key":"1771_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.nmd.2014.04.003","volume":"24","author":"M J\u0119drzejowska","year":"2014","unstructured":"J\u0119drzejowska M, Gos M, Zimowski JG, Kostera-Pruszczyk A, Ryniewicz B, Hausmanowa-Petrusewicz I. Novel point mutations in survival motor neuron 1 gene expand the spectrum of phenotypes observed in spinal muscular atrophy patients. Neuromuscul Disord. 2014;24(7):617\u201323.","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"1771_CR10","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho M, Bernal S, Al\u00edas L, March F, Vencesl\u00e1 A, Rodr\u00edguez-\u00c1lvarez FJ, et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2,834 reported cases. Neuromuscul Disord. 2018;28(3):208\u201315.","journal-title":"Neuromuscul Disord"},{"key":"1771_CR11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s00439-006-0156-7","volume":"119","author":"B Wirth","year":"2006","unstructured":"Wirth B, Wirth \u0106L, Brichta \u0106B, Schrank \u0106H, Lochm\u00fcller S, Blick \u0106A, et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. 2006;119:422\u20138.","journal-title":"Hum Genet"},{"key":"1771_CR12","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1086\/338627","volume":"70","author":"M Feldk\u00f6tter","year":"2002","unstructured":"Feldk\u00f6tter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time light cycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002;70:358\u201368.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"1771_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.18388\/abp.2009_2521","volume":"56","author":"M J\u0119drzejowska","year":"2009","unstructured":"J\u0119drzejowska M, Milewski M, Zimowski J, Borkowska J, Kostera-Pruszczyk A, Sielska D, et al. Phenotype modifiers of spinal muscular atrophy: the number of SMN2 gene copies, deletion in the NAIP gene and probably gender influence the course of the disease. Acta Biochim Pol. 2009;56(1):103\u20138.","journal-title":"Acta Biochim Pol"},{"issue":"1","key":"1771_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00415-013-7154-1","volume":"261","author":"CL Bladen","year":"2014","unstructured":"Bladen CL, Thompson R, Jackson JM, Garland C, Wegel C, Ambrosini A, et al. Mapping the differences in care for 5000 spinal muscular atrophy patients, a survey of 24 national registries in North America Australasia and Europe. J Neurol. 2014;261(1):152\u201363.","journal-title":"J Neurol"},{"key":"1771_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13023-018-0918-z","volume":"13","author":"A Ambrosini","year":"2018","unstructured":"Ambrosini A, Calabrese D, Avato FM, Catania F, Cavaletti G, Pera MC, et al. The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage. Orphanet J Rare Dis. 2018;13:176.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"1771_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3233\/JND-170292","volume":"5","author":"L Belter","year":"2018","unstructured":"Belter L, Cook SF, Crawford TO, Jarecki J, Jones CC, Kissel JT, et al. An overview of the Cure SMA membership database: highlights of key demographic and clinical characteristics of SMA members. J Neuromuscul Dis. 2018;5(2):167\u201376.","journal-title":"J Neuromuscul Dis"},{"issue":"7","key":"1771_CR17","doi-asserted-by":"publisher","first-page":"e0201004","DOI":"10.1371\/journal.pone.0201004","volume":"13","author":"A Chabanon","year":"2018","unstructured":"Chabanon A, Seferian AM, Daron A, P\u00e9r\u00e9on Y, Cances C, Vuillerot C, et al. Prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study. PLoS ONE. 2018;13(7):e0201004.","journal-title":"PLoS ONE"},{"key":"1771_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/jnnp-2016-314292","volume":"88","author":"R Wadman","year":"2017","unstructured":"Wadman R, Stam M, Gijzen M, Lemmink H, Snoeck I, Wijngaarde C, et al. Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0\u20134. J Neurol Neurosurg Psychiatry. 2017;88:365\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1771_CR19","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/ana.25900","volume":"88","author":"G Coratti","year":"2020","unstructured":"Coratti G, Messina S, Lucibello S, Carmela Pera MC, Montes J, Pasternak A, et al. Clinical variability in spinal muscular atrophy type III. Ann Neurol. 2020;88:1109\u201317.","journal-title":"Ann Neurol"},{"issue":"9","key":"1771_CR20","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1136\/jmg.2010.079004","volume":"47","author":"S Bernal","year":"2010","unstructured":"Bernal S, Al\u00edas L, Barcel\u00f3 MJ, Also-Rallo E, Mart\u00ednez-Hern\u00e1ndez R, G\u00e1mez J, et al. The c.859G>C variant in the SMN2 gene is associated with types II and III SMA and originates from a common ancestor. J Med Genet. 2010;47(9):640\u20132.","journal-title":"J Med Genet"},{"issue":"14","key":"1771_CR21","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/hmg\/ddx166","volume":"26","author":"X Wu","year":"2017","unstructured":"Wu X, Wang SH, Sun J, Krainer AR, Hua Y, Prior TW. A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy. Hum Mol Genet. 2017;26(14):2768\u201380.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"1771_CR22","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ejpn.2016.07.017","volume":"20","author":"S Medrano","year":"2016","unstructured":"Medrano S, Monges S, Gravina LP, Al\u0131as L, Mozzoni J, Araoz HV, et al. Genotype phenotype correlation of SMN locus genes in spinal muscular atrophy children from Argentina. Eur J Paediatr Neurol. 2016;20(6):910\u20137.","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"1771_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.nmd.2019.11.002","volume":"30","author":"T Dangouloff","year":"2020","unstructured":"Dangouloff T, Burghes A, Tizzano EF, Servais L. 244th ENMC international workshop: newborn screening in spinal muscular atrophy May 10\u201312, 2019, Hoofdorp, The Netherlands. Neuromuscul Disord. 2020;30(1):93\u2013103.","journal-title":"Neuromuscul Disord"},{"key":"1771_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000052118","volume":"45","author":"S Rudnik-Sch\u00f6neborn","year":"2001","unstructured":"Rudnik-Sch\u00f6neborn S, Hausmanowa-Petrusewicz I, Borkowska J, Zerres K. The predictive value of achieved motor milestones assessed in 441 patients with infantile spinal muscular atrophy types II and III. Eur Neurol. 2001;45:174\u201381.","journal-title":"Eur Neurol"},{"key":"1771_CR25","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/B978-0-12-803685-3.00012-4","volume-title":"Spinal muscular atrophy: disease mechanism and therapy","author":"B Wirth","year":"2017","unstructured":"Wirth B, Mendoza-Ferreira N, Torres-Benito L. Spinal muscular atrophy disease modifiers. In: Sumner CJ, Paushkin S, Ko C-P, editors. Spinal muscular atrophy: disease mechanism and therapy. Amsterdam: Academic Press; 2017. p. 191\u2013210."},{"key":"1771_CR26","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.20473","volume":"57","author":"K Swoboda","year":"2005","unstructured":"Swoboda K, Prior TW, Scott CB, McNaught T, Wride MC, Reyna SP, et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol. 2005;57:704\u201312.","journal-title":"Ann Neurol"},{"issue":"6","key":"1771_CR27","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1136\/jmg.21.6.447","volume":"21","author":"I Hausmanowa-Petrusewicz","year":"1984","unstructured":"Hausmanowa-Petrusewicz I, Zaremba J, Borkowska J, Szirkowiec W. Chronic proximal spinal muscular atrophy of childhood and adolescence: sex influence. J Med Genet. 1984;21(6):447\u201350.","journal-title":"J Med Genet"},{"issue":"8","key":"1771_CR28","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/ejhg.2008.41","volume":"16","author":"M J\u0119drzejowska","year":"2008","unstructured":"J\u0119drzejowska M, Borkowska J, Zimowski J, Kostera-Pruszczyk A, Milewski M, Jurek M, et al. Unaffected patients with a homozygous absence of the SMN1 gene. Eur J Hum Genet. 2008;16(8):930\u20134.","journal-title":"Eur J Hum Genet"},{"key":"1771_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00439-008-0598-1","volume":"125","author":"L Al\u00edas","year":"2009","unstructured":"Al\u00edas L, Bernal S, Fuentes-Prior P, Barcel\u00f3 MJ, Also E, Mart\u00ednez-Hern\u00e1ndez R, et al. Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene. Hum Genet. 2009;125:29\u201339.","journal-title":"Hum Genet"},{"key":"1771_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00415-005-0912-y","volume":"253","author":"I Cusc\u00f3","year":"2006","unstructured":"Cusc\u00f3 I, Barcel\u00f3 MJ, Rojas-Garc\u00eda R, Illa I, G\u00e1mez J, Cervera C, et al. SMN2 copy number predicts acute or chronic spinal muscular atrophy but does not account for intrafamilial variability in siblings. J Neurol. 2006;253:21\u20135.","journal-title":"J Neurol"},{"issue":"5875","key":"1771_CR31","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1126\/science.1155085","volume":"320","author":"GE Oprea","year":"2008","unstructured":"Oprea GE, Kr\u00f6ber S, McWhorter ML, Rossoll W, M\u00fcller S, Krawczak M, et al. Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science. 2008;320(5875):524\u20137.","journal-title":"Science"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01771-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-021-01771-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01771-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T20:11:52Z","timestamp":1616616712000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01771-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1771"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01771-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,24]]},"assertion":[{"value":"25 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Medical University of Warsaw (BK\/180\/2008). Written informed consent was obtained from patients, or the parents or legal guardians of patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and Consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Anna Lusakowska is a sub-investigator in clinical trials for patients with SMA (funded by Roche) and Duchenne muscular dystrophy (funded by PTC), receives institutional Grant support from Biogen, and is a lecturer on neuromuscular diseases supported by Biogen and Roche. Maria Jedrzejowska reports participation in scientific advisory boards for Biogen and Avexis\/Novartis, receives honoraria for lectures from Biogen and travel support from Biogen and Roche, and acts as a sub-investigator in Roche trials of olesoxime and risdiplam for SMA. Anna Kaminska declares no conflicts of interest. Katarzyna Janiszewska declares no conflicts of interest. Przemys\u0142aw Grochowski declares no conflicts of interest. Janusz Zimowski declares no conflicts of interest. Janusz Sierdzinski declares no conflicts of interest. Anna Kostera Pruszczyk reports lecture honoraria and travel support from Biogen, Roche, PTC, Avexis, and Novartis, institutional Grant support from Biogen, and advisory board honoraria from Biogen, Roche, Avexis, and Novartis, and is a principal investigator for Roche SMA studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}